Lilly reports fast sales for new diabetes drug
Bio Pharma Dive
FEBRUARY 2, 2023
Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.
Antibody 
291
291 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is a monoclonal antibody that targets amyloid beta A4 protein and acts by selectively binding and eliminating amyloid beta plaques, thought to be clinically significant for the treatment of Alzheimer’s disease.
Sales 147
147 
Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is a monoclonal antibody that targets amyloid beta A4 protein and acts by selectively binding and eliminating amyloid beta plaques, thought to be clinically significant for the treatment of Alzheimer’s disease.
Sales 130
130 
Daiichi Sankyo again dials up Enhertu sales forecast, advances 2nd AstraZeneca-partnered ADC
Fierce Pharma
JANUARY 31, 2024
AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.<
Sales 87
87 
GSK beats forecasts, thanks to COVID antibody and Shingrix sales
pharmaphorum
APRIL 27, 2022
GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 billion with no sales recorded in the prior year.
Sales 80
80 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale
Fierce Pharma
MAY 6, 2024
In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ADC Therapeutics provided several company updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded (..)
Sales 94
94 
Antibody aficionado Abcam explores strategic alternatives—including a potential sale
Fierce Pharma
JUNE 29, 2023
Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking t | Half a decade after Abcam quit its £270 million pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the (..)
Antibody 79
79 
Where is the opportunity in the therapeutic antibody market?
Drug Discovery World
APRIL 8, 2024
Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. Dr Levy will outline the significance of belimumab, a monoclonal antibody that inhibits B-cell activating factor. What effect has antibody engineering had on drug discovery and development?
Antibody 59
59 
Where is the opportunity in the therapeutic antibody market?
Drug Discovery World
MAY 7, 2024
In this webinar, you will hear from Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader – Scientific Solutions Consulting at Benchling, and Dr Paola Genevini, Technical Sales Specialist at Bio-Rad.
Antibody 52
52 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.
Antibody 130
130 
Webinar: How can we develop better therapeutic antibodies?
Drug Discovery World
APRIL 22, 2024
Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?
Antibody 52
52 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.
Antibody 130
130 
After Catalent rumors, Danaher strikes $5.7B deal to acquire antibody specialist Abcam
Fierce Pharma
AUGUST 28, 2023
It’s a sale. Two months after Abcam launched a strategic review of the company, the British antibody research expert has revealed that it’s being bought by Danaher. Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday.
Antibody 98
98 
Opportunity in the therapeutic antibody market: Hear from the experts
Drug Discovery World
APRIL 29, 2024
Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?
Antibody 52
52 
Webinar: Innovations and opportunities in the therapeutic antibody market
Drug Discovery World
APRIL 15, 2024
Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?
Antibody 52
52 
Partners to discover antibodies for autoimmune diseases
Drug Discovery World
SEPTEMBER 12, 2023
Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono.
Antibody 72
72 
Where is the opportunity in the therapeutic antibody market?
Drug Discovery World
APRIL 8, 2024
Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?
Antibody 52
52 
XBiotech Announces Receipt of $75 Million from Sale of Antibody
BioTech 365
JUNE 30, 2021
XBiotech Announces Receipt of $75 Million from Sale of Antibody XBiotech Announces Receipt of $75 Million from Sale of Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody AUSTIN, Texas, June 30, … Continue reading →
Sales 40
40 
Merck Touts Strong Growth in Keytruda Sales, ADC Business in Q3
BioSpace
OCTOBER 26, 2023
billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3
Sales 117
117 
Antibody development drives high-value biotech deals
Drug Discovery World
SEPTEMBER 6, 2023
The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature. In 2022, there were 156 antibody-focused deals with a value of $57.3 Reference [link] The post Antibody development drives high-value biotech deals appeared first on Drug Discovery World (DDW).
Antibody 52
52 
Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate
Roots Analysis
FEBRUARY 27, 2024
Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. Check the details of the agreement here.
Antibody 40
40 
Regeneron tries to shake off fall in COVID drug sales with first quarter earnings
Bio Pharma Dive
MAY 4, 2022
revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.
Sales 148
148 
Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4
Sales 85
85 
Collaboration to identify up to 10 novel target-antibody pairs
Drug Discovery World
JANUARY 11, 2023
AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . The post Collaboration to identify up to 10 novel target-antibody pairs appeared first on Drug Discovery World (DDW).
Antibody 52
52 
Eli Lilly’s COVID-19 Monoclonal Antibodies Cleared to Battle Delta
XTalks
SEPTEMBER 7, 2021
After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant. 1 and Beta/B.1.351, 1.351, respectively). “The
Antibody 97
97 
Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year
pharmaphorum
FEBRUARY 8, 2022
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. Pfizer shares actually fell in the wake of its results announcement as some analysts had been forecasting higher sales for Comirnaty this year.
Sales 94
94 
After withdrawal, GSK touts another Blenrep combo win as analysts build blockbuster case for the myeloma ADC
Fierce Pharma
MARCH 7, 2024
GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.
Antibody 101
101 
GSK gets £1.4bn sales lift from COVID-19 products in 2021
pharmaphorum
FEBRUARY 9, 2022
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.
Sales 88
88 
Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter
pharmaphorum
AUGUST 6, 2021
billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2
Sales 105
105 
Jazz acquires rights to HER2-targeted bispecific antibody
Drug Discovery World
OCTOBER 21, 2022
billion, plus royalties on net sales. Zanidatamab is a HER2-targeted bispecific antibody with novel mechanisms of action. The post Jazz acquires rights to HER2-targeted bispecific antibody appeared first on Drug Discovery World (DDW).
Antibody 52
52 
Strike two for Novartis’ lung cancer antibody canakinumab
pharmaphorum
OCTOBER 25, 2021
Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.
Antibody 116
116 
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Pharmaceutical Technology
MAY 30, 2023
Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda.
Drugs 264
264 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.
Research 130
130 
Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates
Roots Analysis
OCTOBER 25, 2023
On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72
Antibody 40
40 
Regeneron reports 7 per cent rise in Q1 2023 total revenue
Pharmaceutical Technology
MAY 5, 2023
In the US, Eylea’s (aflibercept) net product sales decreased by 6% to $1.43bn from $1.5bn in Q1 2022 owing to a rise in sales-related deductions, partly offset by higher sales volume. Worldwide net sales of Dupixent increased by 37% to $2.49bn Q1 to Q1 2022-23. “We
Sales 130
130 
Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody
pharmaphorum
OCTOBER 18, 2022
Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7
Antibody 52
52 
US signs $1bn order for GSK, Vir’s COVID-19 antibody
pharmaphorum
NOVEMBER 17, 2021
The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion. The post US signs $1bn order for GSK, Vir’s COVID-19 antibody appeared first on. Another phase 3 trial called COMET-STAR is assessing whether.
Antibody 52
52 
Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Pharmaceutical Technology
APRIL 3, 2023
Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
Development 130
130 
GSK sees £20bn peak sales potential in late-stage pipeline
pharmaphorum
JUNE 23, 2021
GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.
Sales 75
75 
Cullinan Oncology signs licence deal with Harbour BioMed
Pharmaceutical Technology
FEBRUARY 14, 2023
HBM7008 has been developed from HBICE, a next-generation heavy chain-only antibody (HCAb)-based multi-specific antibody discovery platform. CLN-418 is a strong strategic fit for Cullinan, building on our expertise with bispecifics and placing us at the forefront of bispecific antibody development in solid tumours.”
Antibody 130
130 
Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth
Pharmaceutical Technology
SEPTEMBER 15, 2022
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
Vaccination 272
272 
Let's personalize your content